Q32 Bio Inc., a clinical stage biotechnology company, has released its financial results for the second quarter of 2025. The company reported cash and cash equivalents of $54.8 million as of June 30, 2025, which it expects to be sufficient to fund operations into 2027. The net loss for the three-month period ended June 30, 2025, was $9.5 million, compared to a net loss of $17.0 million for the same period in 2024. The reduction in net loss is reflected in a decrease in research and development expenses, which fell to $5.2 million from $13.4 million in the prior year, primarily due to lower bempikibart development costs and restructuring actions. General and administrative expenses also decreased to $4.0 million from $4.5 million, attributed to reduced headcount and legal costs. The company is continuing its development program for bempikibart, with patient dosing ongoing in the Part A open-label extension and Part B of the SIGNAL-AA trial. The topline data readout for Part B is on track for the first half of 2026. Additionally, Q32 Bio has appointed Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer to strengthen its leadership team.